Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods : A Scientific Statement From the American Heart Association: Endorsed by the Pediatric & Congenital Electrophysiology Society (PACES)
Disorders of the cardiac rhythm may occur in both the fetus and neonate. Because of the immature myocardium, the hemodynamic consequences of either bradyarrhythmias or tachyarrhythmias may be far more significant than in mature physiological states. Treatment options are limited in the fetus and neonate because of limited vascular access, patient size, and the significant risk/benefit ratio of any intervention. In addition, exposure of the fetus or neonate to either persistent arrhythmias or antiarrhythmic medications may have yet-to-be-determined long-term developmental consequences. This scientific statement discusses the mechanism of arrhythmias, pharmacological treatment options, and distinct aspects of pharmacokinetics for the fetus and neonate. From the available current data, subjects of apparent consistency/consensus are presented, as well as future directions for research in terms of aspects of care for which evidence has not been established.
| Errataetall: |
ErratumIn: Circulation. 2024 Mar 19;149(12):e996. - PMID 38498614 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
Circulation - 149(2024), 10 vom: 05. März, Seite e937-e952 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Batra, Anjan S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AHA Scientific Statements |
|---|
| Anmerkungen: |
Date Completed 06.03.2024 Date Revised 03.04.2024 published: Print-Electronic ErratumIn: Circulation. 2024 Mar 19;149(12):e996. - PMID 38498614 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIR.0000000000001206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368037541 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368037541 | ||
| 003 | DE-627 | ||
| 005 | 20240404234728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240205s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIR.0000000000001206 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM368037541 | ||
| 035 | |a (NLM)38314551 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Batra, Anjan S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods |b A Scientific Statement From the American Heart Association: Endorsed by the Pediatric & Congenital Electrophysiology Society (PACES) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Circulation. 2024 Mar 19;149(12):e996. - PMID 38498614 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Disorders of the cardiac rhythm may occur in both the fetus and neonate. Because of the immature myocardium, the hemodynamic consequences of either bradyarrhythmias or tachyarrhythmias may be far more significant than in mature physiological states. Treatment options are limited in the fetus and neonate because of limited vascular access, patient size, and the significant risk/benefit ratio of any intervention. In addition, exposure of the fetus or neonate to either persistent arrhythmias or antiarrhythmic medications may have yet-to-be-determined long-term developmental consequences. This scientific statement discusses the mechanism of arrhythmias, pharmacological treatment options, and distinct aspects of pharmacokinetics for the fetus and neonate. From the available current data, subjects of apparent consistency/consensus are presented, as well as future directions for research in terms of aspects of care for which evidence has not been established | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a AHA Scientific Statements | |
| 650 | 4 | |a arrhythmias, cardiac | |
| 650 | 4 | |a fetus | |
| 650 | 4 | |a heart block | |
| 650 | 4 | |a infant, newborn | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a tachycardia | |
| 700 | 1 | |a Silka, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Borquez, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Cuneo, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Dechert, Brynn |e verfasserin |4 aut | |
| 700 | 1 | |a Jaeggi, Edgar |e verfasserin |4 aut | |
| 700 | 1 | |a Kannankeril, Prince J |e verfasserin |4 aut | |
| 700 | 1 | |a Tabulov, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Tisdale, James E |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfe, Diana |e verfasserin |4 aut | |
| 700 | 0 | |a American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Genomic and Precision Medicine, and Council on Lifelong Congenital Heart Disease and Heart Health in the Young |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d 1950 |g 149(2024), 10 vom: 05. März, Seite e937-e952 |w (DE-627)NLM000039020 |x 1524-4539 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2024 |g number:10 |g day:05 |g month:03 |g pages:e937-e952 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIR.0000000000001206 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2024 |e 10 |b 05 |c 03 |h e937-e952 | ||